4,901 trials
Scleroderma, Systemic
Primary: Area Under the Concentration-time Curve of Ethinylestradiol in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz) — 610.00; 618.28…
Severe Hepatic Impairment
Primary: Maximum Observed Plasma Concentration (Cmax) of Dacomitinib — 9.673; 7.389 nanogram per milliliter
Multiple Myeloma
Primary: Number of Participants With Adverse Events (AEs) — 10; 12; 34; 9 Participants
Cardiomyopathy Due to Anthracyclines
Primary: Proportion of Major Adverse Cardiac Events (MACE) — 3; 6 events
Cystic Fibrosis · Burkholderia Cepacia Infection
Primary: The Change in Sputum Density of BCC in Colony Forming Units (CFUs)/ml From Day 0 to Day 28 of TIP Treatment. — -1.4 CFU/ml log10
Healthy
Primary: AUC0 - t — 19704.2; 20736.9 h*ug/mL — p=>0.05
COVID 19
Primary: Number of Cured Patients — 16 Participants
Diabetes Mellitus
Primary: Number of Participants With Clinically Significant Physical Examination Abnormalities — 0; 0; 0; 0 participants
Healthy Volunteers
Primary: Mass Balance Recovery of Total Radioactivity: CumAe (Urine) — 70.9 mg equiv
Healthy
Primary: Relative Potency Max Heart Rate — 0.8619 unitless — p=>0.10
Respiratory Syncytial Virus
Primary: Number of Subjects Reporting Local Reactogenicity Signs and Symptoms Within 7 Days of the First Product Administration of DS-Cav1 Alone or With Alum Adjuvant — 6; 5; 11…
Malignant Melanoma
Primary: Number of Patients With Treatment-emergent Adverse Events (TEAEs) — 8; 8; 0; 0 Participants
Neoplasms
Primary: Number of Participants With Non-serious Adverse Events (Non-SAEs) and Serious Adverse Events (SAEs) During run-in Period — 11; 1 Participants
Enoxaparin Sodium is Administered to Healthy Volunteers
Primary: Cmax (Anti-FXa and Anti-FIIa) — 0.8593; 0.8698; 0.1187; 0.1296 IU/mL
Driving Impaired
Primary: Standard Deviation of Lateral Position (SDLP) — 29.3; 29.7; 38.6 cm of deviation of lateral position